SESSION TITLE: Chest infections Posters II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM
PURPOSE: Community-acquired pneumonia (CAP) is a cause of considerable morbidity and mortality worldwide. Knowing the burden of CAP is important for taking preventive measures to control the disease, minimize the risk of complications, and reduce treatment and rehabilitation costs. The present study aimed to calculate the direct costs of CAP in adults >18 years of age.
METHODS: Outpatient and inpatient data of CAP cases were retrospectively evaluated for 18 months period. Numbers of radiological and laboratory analyses, hospitalization (day), and specialist visit were multiplied by the relevant reimbursed unit costs and direct medical cost per patient was calculated. Total drug costs for inpatients and outpatients were calculated based on daily drug dose, treatment duration, and reimbursed drug cost.
RESULTS: The mean age of inpatients (n=211) was 61.56±17.87 years and 51.4% of them were male, whereas it was 53.78±17.46 years for outpatients (n=208), of whom 53.8% were male. The rates of inpatients and outpatients aged ≥65 years were 48.6% and 28.9%, respectively. Total median cost (minimum-maximum) was 870.04 TL (217.81TL-28,623.45TL) for the inpatients and 114.35 TL (15.5TL-668TL) for the outpatients. In the inpatients, while drug cost, cost of hospitalization and total cost (908.0TL vs. 753.7TL) were significantly higher in males, costs of laboratory analysis, drug, and hospital stay (day), and total cost (1,001.1TL vs. 821.7TL) were significantly higher in those aged ≥65 years. There were no significant differences between gender and age groups regarding each cost parameter and total cost in the outpatients. The costs of specialist visit, radiological and laboratory analyses, drug, hospital stay (day) and total cost (1,837.8TL vs. 785.0TL) were significantly higher in those with more than one hospitalization (n=17) than those with only one hospitalization (n=191) in the study period. The costs of specialist visit, radiological and laboratory analyses, drug and total cost (485.2TL vs. 168.8TL) were significantly higher in those with comorbidities (n=314) than those without (n=98).
CONCLUSIONS: Costs were higher in patients with advanced age, comorbidities, and more than one hospitalization.
CLINICAL IMPLICATIONS: Preventive actions will decrease the incidence of disease as well as the cost of treatment, hospitalization and total costs associated with disease especially in patient groups aged ≥65 years and aged between 19-64 years with comorbidity in adult population.
DISCLOSURE: The following authors have nothing to disclose: Filiz Kosar, Çağlar Çuhadaroğlu
No Product/Research Disclosure Information